首页> 中文期刊> 《临床医学研究与实践》 >早期足量甲基强的松龙联合丙种免疫球蛋白在重症手足口病治疗中的效果分析

早期足量甲基强的松龙联合丙种免疫球蛋白在重症手足口病治疗中的效果分析

         

摘要

目的:分析早期应用足量甲基强的松龙联合丙种球蛋白对重症手足口病患儿实施治疗的临床效果。方法选择我院收治的重症手足口病患儿92例,将其按照随机数字表法分为对照组和治疗组,每组46例。对照组患儿采用临床常规手足口病治疗方案进行治疗;治疗组在常规方案基础上,早期应用足量甲基强的松龙联合丙种球蛋白进行治疗。结果治疗组患儿手足口病症状消失时间和临床药物治疗计划实施总时间明显短于对照组;用药期间出现的不良反应明显少于对照组;重症手足口病药物治疗效果明显优于对照组,差异均具有统计学意义( P<0.05)。结论早期应用足量甲基强的松龙联合丙种免疫球蛋白对重症手足口病进行治疗,临床效果显著。%ABS TRACT: Objective To study the clinical effect of early application of adequate methylprednisolone combined fetal immune globulins in the treatment of severe hand-foot-and-mouth disease. Methods Ninety-two cases of children with severe hand-foot-and-mouth disease in our hospital were selected, and randomly divided into control group and treatment group, with 46 cases in each group. Clinical routine treatment of hand-foot-and-mouth was used to the children in control group. Early application of adequate methylprednisolone combined fetal immune globulins were additionally used to the children in treatment group. Results The symptoms disappearing time and clinical drug treatment planning to implement the total time of the children in treatment group is obviously shorter than that of the children in control group; The drug adverse reactions is less than that of control group; the drug therapy efficacy to severe hand-foot-and-mouth disease is better than that in the control group. Conclusion Early application of adequate methylprednisolone combines fetal immune globulins in treatment to severe hand-foot-and-mouth disease is remarkable to cure the disease.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号